EVTA Stock Chart & Stats
€1.54
€0.02(1.28%)
At close: 4:00 PM EDT
€1.54
€0.02(1.28%)
Day’s Range― - ―
52-Week Range€1.29 - €3.54
Previous CloseN/A
Volume0.00
Average Volume (3M)547.00
Market Cap
€508.11M
Enterprise Value€1.01K
Total Cash (Recent Filing)€465.59M
Total Debt (Recent Filing)€475.87M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 05, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding355,819,950
10 Day Avg. Volume35
30 Day Avg. Volume547
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.41Price Target Upside56.69% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.58
Revenue Forecast (FY)€595.83M
Bulls Say, Bears Say
Bulls Say
Integrated Drug Discovery PlatformEvotec’s integrated capabilities let partners access multiple stages of therapeutic development through one platform, supporting customer retention and broader program participation. This model can deepen strategic relationships and create recurring service, milestone and downstream revenue opportunities.
Biologics And Biodefense CapabilitiesThe JST-018 program demonstrates that Evotec can combine antibody discovery, process development, regulatory work and clinical manufacturing within its biologics platform. Progress into Phase 1 and biodefense work strengthens its specialized positioning and supports potential contracted revenue.
Transformation And Partnership PipelineEvotec is pursuing a multi-year operating transformation while continuing to add collaborations, grants and milestone opportunities. If execution is successful, the savings program could improve the cost base, while partnership activity preserves strategic optionality across discovery and biologics.
Bears Say
Declining Revenue And Lowered OutlookThe sharp first-half revenue decline and reduced full-year outlook indicate weaker near-term conversion of contracted activity into reported sales. Sustained softness would limit operating scale, reduce funds available for investment and make recovery dependent on improved execution and customer demand.
Persistent Losses And Margin CompressionNegative profitability and substantially lower gross margins show that Evotec is not currently converting its platform and services into consistent earnings. Persistent margin pressure can weaken reinvestment capacity and make the business more exposed to program mix, pricing and cost execution.
Negative Operating And Free Cash FlowCash consumption means the business is not presently funding operations and investment internally, increasing reliance on liquidity or external financing. Until operating cash flow turns sustainably positive, ongoing losses could reduce financial flexibility and constrain the pace of platform development.
Evotec AG News
EVTA FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was €1.29 and its highest was €3.54 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is €508.11M.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Aug 13, 2026. The company reported -€0.13 earnings per share for the quarter, missing the consensus estimate of -€0.035 by -€0.095.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.23.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,950 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -€0.13 in its last earnings report, missing expectations of -€0.035. Following the earnings report the stock price went down -7.447%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in DE:EVTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.41 (56.69% Upside)
€2.41 (56.69% Upside)
Blogger Sentiment
Bullish
DE:EVTA Sentiment 67%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVTA Company Deck
EVTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: near-term financials were weak with material revenue declines (H1 revenues down ~19%) and negative adjusted EBITDA (H1 EUR -42.7m), and management revised full-year 2026 guidance downward due mainly to timing shifts in strategic partnership milestone recognition. Offsetting these weaknesses are encouraging commercial leading indicators (inbound inquiries +~30%, proposals >45%, base D&PD net sales +~28% in H1), a healthy pipeline of 10–20 strategic partnership opportunities, strong liquidity (EUR 465.6m), active cost-savings via the Horizon program (~EUR 75m run-rate by 2027), and recent senior hires to improve commercial conversion. Overall, the issues appear driven largely by timing and phasing rather than loss of pipeline quality, but 2026 results and guidance remain meaningfully impacted.View all DE:EVTA earnings summariesEVTA Stock 12 Month Forecast
Average Price Target
€2.41
▲(56.69% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―